TherapeuticsMD Inc banner

TherapeuticsMD Inc
NASDAQ:TXMD

Watchlist Manager
TherapeuticsMD Inc Logo
TherapeuticsMD Inc
NASDAQ:TXMD
Watchlist
Price: 2.19 USD 0.46% Market Closed
Market Cap: $25.3m

EV/S

5.9
Current
12%
Cheaper
vs 3-y average of 6.7

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
5.9
=
Enterprise Value
$16.9m
/
Revenue
$3m

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
5.9
=
Enterprise Value
$16.9m
/
Revenue
$3m

Valuation Scenarios

TherapeuticsMD Inc is trading below its 3-year average

If EV/S returns to its 3-Year Average (6.7), the stock would be worth $2.5 (14% upside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-49%
Maximum Upside
+14%
Average Downside
19%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 5.9 $2.19
0%
3-Year Average 6.7 $2.5
+14%
5-Year Average 5.8 $2.15
-2%
Industry Average 3.6 $1.32
-40%
Country Average 3 $1.13
-49%

Forward EV/S
Today’s price vs future revenue

Not enough data available to calculate forward EV/S

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
US
TherapeuticsMD Inc
NASDAQ:TXMD
25.3m USD 5.9 -44.5
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 13.3 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 6 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 5.2 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 5.2 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 4.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 108.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 4.1 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 3.2 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 3.1 16.8
P/E Multiple
Earnings Growth PEG
US
TherapeuticsMD Inc
NASDAQ:TXMD
Average P/E: 21.9
Negative Multiple: -44.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Higher than 73% of companies in the United States of America
Percentile
73rd
Based on 11 256 companies
73rd percentile
5.9
Low
0 — 1.6
Typical Range
1.6 — 5.3
High
5.3 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 1.6
Median 3
70th Percentile 5.3
Max 4 613 320.1

TherapeuticsMD Inc
Glance View

Market Cap
25.3m USD
Industry
Pharmaceuticals

TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 416 full-time employees. The company went IPO on 2001-01-31. Its contraceptive products include ANNOVERA. ANNOVERA (segesterone acetate (SA) and ethinyl estradiol (EE) vaginal system) is a one-year ring-shaped contraceptive vaginal system (CVS) and patient-controlled, procedure-free, reversible prescription contraceptive. Its menopause portfolio includes IMVEXXY and BIJUV. IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause. (estradiol and progesterone) capsules is a bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. Its prenatal vitamin products include vitaTrue, vitaPearl, and BocaGreenMD Prena1 True.

TXMD Intrinsic Value
Not Available
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett